1. Home
  2. CRNX vs GFF Comparison

CRNX vs GFF Comparison

Compare CRNX & GFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$41.08

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Griffon Corporation

GFF

Griffon Corporation

HOLD

Current Price

$91.00

Market Cap

4.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
GFF
Founded
2008
1959
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building Products
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.1B
IPO Year
2018
1994

Fundamental Metrics

Financial Performance
Metric
CRNX
GFF
Price
$41.08
$91.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
3
Target Price
$76.75
$105.00
AVG Volume (30 Days)
968.2K
364.5K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
0.99%
EPS Growth
N/A
N/A
EPS
N/A
1.41
Revenue
$1,039,000.00
$2,519,926,000.00
Revenue This Year
$720.10
N/A
Revenue Next Year
$184.67
N/A
P/E Ratio
N/A
$64.60
Revenue Growth
N/A
N/A
52 Week Low
$25.83
$65.01
52 Week High
$57.99
$97.58

Technical Indicators

Market Signals
Indicator
CRNX
GFF
Relative Strength Index (RSI) 60.96 64.96
Support Level $39.88 $73.09
Resistance Level $41.33 $96.39
Average True Range (ATR) 1.52 3.05
MACD 0.27 -0.01
Stochastic Oscillator 76.34 84.59

Price Performance

Historical Comparison
CRNX
GFF

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About GFF Griffon Corporation

Griffon Corp manufactures and markets residential, commercial and industrial garage doors to professional installing dealers and home center retail chains. It also provides non-powered landscaping products for homeowners and professionals. Its operating segments include Consumer and Professional Products: is a provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and Home and Building Products conducts its operations through Clopay Corporation (Clopay). Clopay is the manufacturer and marketer of garage doors and rolling steel doors in North America. The company generates a majority of its revenue from the Home and Building Products segment. Operates in USA, Europe, Canada, Australia, and Others.

Share on Social Networks: